{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T07:05:06Z","timestamp":1790060706208,"version":"4.0.1"},"reference-count":57,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T00:00:00Z","timestamp":1762819200000},"content-version":"am","delay-in-days":314,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000025","name":"National Institute of Mental Health","doi-asserted-by":"publisher","award":["T32 MH 013043"],"award-info":[{"award-number":["T32 MH 013043"]}],"id":[{"id":"10.13039\/100000025","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jsatjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Substance Use and Addiction Treatment"],"published-print":{"date-parts":[[2025,1]]},"DOI":"10.1016\/j.josat.2024.209568","type":"journal-article","created":{"date-parts":[[2024,11,4]],"date-time":"2024-11-04T08:28:02Z","timestamp":1730708882000},"page":"209568","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Medicaid expansion and medications to treat opioid use disorder in outpatient specialty care from 2010 to 2020"],"prefix":"10.1016","volume":"168","author":[{"given":"Rachel","family":"Presskreischer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ramin","family":"Mojtabai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Mauro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhijun","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melanie","family":"Wall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Olfson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.josat.2024.209568_bb0010","series-title":"Efficient estimation of maximum likelihood models with multiple fixed-effects: The R package FENmlm","author":"Berge","year":"2018"},{"issue":"1","key":"10.1016\/j.josat.2024.209568_bb0015","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1162\/003355304772839588","article-title":"How much should we trust differences-in-differences estimates?","volume":"119","author":"Bertrand","year":"2004","journal-title":"The Quarterly Journal of Economics"},{"key":"10.1016\/j.josat.2024.209568_bb0020","unstructured":"Blair G., Cooper J., Coppock A., Humphreys M. & Sonnet L. (2022). _estimatr: Fast estimators for design-based Inference_. R package version 1.0.0, https:\/\/CRAN.R-project.org\/package=estimatr."},{"issue":"10","key":"10.1016\/j.josat.2024.209568_bb0025","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1001\/jamapsychiatry.2021.1969","article-title":"Contingency management for patients receiving medication for opioid use disorder: A systematic review and meta-analysis","volume":"78","author":"Bol\u00edvar","year":"2021","journal-title":"JAMA Psychiatry"},{"issue":"2","key":"10.1016\/j.josat.2024.209568_bb0030","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.drugalcdep.2003.10.012","article-title":"Prescription opioid abuse in patients presenting for methadone maintenance treatment","volume":"73","author":"Brands","year":"2004","journal-title":"Drug and Alcohol Dependence"},{"issue":"16","key":"10.1016\/j.josat.2024.209568_bb0035","doi-asserted-by":"crossref","first-page":"1530","DOI":"10.1056\/NEJMc2312906","article-title":"Buprenorphine dispensing after elminitation of the waiver requirements","volume":"390","author":"Chua","year":"2024","journal-title":"New England Journal of Medicine"},{"key":"10.1016\/j.josat.2024.209568_bb0040","doi-asserted-by":"crossref","DOI":"10.1016\/j.drugpo.2023.104141","article-title":"Typology of laws restricting access to methadone treatment in the United States: A latent class analysis","volume":"119","author":"Conway","year":"2023","journal-title":"International Journal of Drug Policy"},{"key":"10.1016\/j.josat.2024.209568_bb0045","doi-asserted-by":"crossref","DOI":"10.1016\/j.psychres.2023.115318","article-title":"Meta-review on the efficacy of psychological therapies for the treatment of substance use disorders","volume":"326","author":"Dellazizzo","year":"2023","journal-title":"Psychiatry Research"},{"issue":"3","key":"10.1016\/j.josat.2024.209568_bb0055","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1177\/10600280211028262","article-title":"Pronounced regional disparities in United States methadone distribution","volume":"56","author":"Furst","year":"2022","journal-title":"Annals of Pharmacotherapy"},{"issue":"3","key":"10.1016\/j.josat.2024.209568_bb0060","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1111\/1475-6773.13282","article-title":"The effect of Medicaid expansion on use of opioid agonist treatment and the role of provider capacity constraints","volume":"55","author":"Gertner","year":"2020","journal-title":"Health Services Research"},{"issue":"2","key":"10.1016\/j.josat.2024.209568_bb0065","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1016\/j.jeconom.2021.03.014","article-title":"Difference-in-differences with variation in treatment timing","volume":"225","author":"Goodman-Bacon","year":"2021","journal-title":"Journal of Econometrics"},{"key":"10.1016\/j.josat.2024.209568_bb0070","series-title":"CBHSQ data review, 1\u201315","article-title":"State and sociodemographic variations in substance use treatment need and receipt in the United States","author":"Han","year":"2011"},{"key":"10.1016\/j.josat.2024.209568_bb0075","doi-asserted-by":"crossref","DOI":"10.1016\/j.drugalcdep.2024.111251","article-title":"Unmet need for medication for opioid use disorder among persons who inject drugs in 23 U.S. cities","volume":"257","author":"Handanagic","year":"2024","journal-title":"Drug and Alcohol Dependence"},{"key":"10.1016\/j.josat.2024.209568_bb0080","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.drugalcdep.2016.03.028","article-title":"Buprenorphine and methodone treatment for opioid dependence by income, ethnicity and race of neighborhoods in new York City","volume":"164","author":"Hansen","year":"2016","journal-title":"Drug and Alcohol Dependence"},{"issue":"2","key":"10.1016\/j.josat.2024.209568_bb0085","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/j.jsat.2008.07.002","article-title":"Predictors of opiate agonist treatment retention among injection drug users referred from a needle exchange program","volume":"36","author":"Havens","year":"2009","journal-title":"Journal of Substance Use & Addiction Treatment"},{"issue":"1","key":"10.1016\/j.josat.2024.209568_bb2085","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1177\/1073110519840498","article-title":"Innovative law and policy responses to the opioid crisis","volume":"47","author":"Hodge","year":"2019","journal-title":"The Journal of Law, Medicine & Ethics"},{"issue":"8","key":"10.1016\/j.josat.2024.209568_bb0090","doi-asserted-by":"crossref","first-page":"e55","DOI":"10.2105\/AJPH.2015.302664","article-title":"National and state treatment need and capacity for opioid agonist medication-assisted treatment","volume":"105","author":"Jones","year":"2015","journal-title":"American Journal of Public Health"},{"issue":"8","key":"10.1016\/j.josat.2024.209568_bb0095","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2023.27488","article-title":"Use of medication for opioid use disorder among adults with past-year opioid use disorder in the US, 2021","volume":"6","author":"Jones","year":"2023","journal-title":"JAMA Network Open"},{"issue":"10","key":"10.1016\/j.josat.2024.209568_bb0100","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1001\/jamapsychiatry.2022.2284","article-title":"Receipt of telehealth services, receipt and retention of medications for opioid use disorder, and medically treated overdose among Medicare beneficiaries before and during the COVID-19 pandemic","volume":"79","author":"Jones","year":"2022","journal-title":"JAMA Psychiatry"},{"key":"10.1016\/j.josat.2024.209568_bb0105","series-title":"April 8","author":"KFF","year":"2024"},{"issue":"2","key":"10.1016\/j.josat.2024.209568_bb0110","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2024.0209","article-title":"Accessibility of opioid treatment programs based on conventional vs perceived travel time measures","volume":"7","author":"Kim","year":"2024","journal-title":"JAMA Network Open"},{"issue":"4","key":"10.1016\/j.josat.2024.209568_bb0115","doi-asserted-by":"crossref","first-page":"348","DOI":"10.3109\/15360288.2012.734905","article-title":"Characterization of prescription opioid abuse in the United States: Focus on route of administration","volume":"26","author":"Kirsh","year":"2012","journal-title":"Journal of Pain Palliative Care Pharmacotherapy"},{"key":"10.1016\/j.josat.2024.209568_bb0120","doi-asserted-by":"crossref","DOI":"10.1016\/j.drugpo.2022.103786","article-title":"Has the treatment gap for opioid use disorder narrowed in the U.S.?: A yearly assessment from 2010 to 2019","volume":"110","author":"Krawczyk","year":"2022","journal-title":"International Journal of Drug Policy"},{"issue":"2","key":"10.1016\/j.josat.2024.209568_bb0125","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1002\/pam.22112","article-title":"The effect of public insurance expansions on substance use disorder treatment: Evidence from the affordable care act","volume":"38","author":"Maclean","year":"2019","journal-title":"Journal of Policy Analysis and Management"},{"key":"10.1016\/j.josat.2024.209568_bb0130","first-page":"CD002207","article-title":"Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence","volume":"2","author":"Mattick","year":"2014","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"2","key":"10.1016\/j.josat.2024.209568_bb0135","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1001\/jama.2021.7374","article-title":"Use of medications for treatment of opioid use disorder among US Medicaid enrollees in 11 states, 2014-2018","volume":"326","author":"Medicaid Outcomes Distributed Research, N","year":"2021","journal-title":"Journal of the American Medical Association"},{"key":"10.1016\/j.josat.2024.209568_bb0140","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.jhealeco.2018.06.004","article-title":"The role of health insurance on treatment for opioid use disorders: Evidence from the affordable care act Medicaid expansion","volume":"60","author":"Meinhofer","year":"2018","journal-title":"Journal of Health Economics"},{"issue":"1","key":"10.1016\/j.josat.2024.209568_bb0145","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1377\/hlthaff.2018.05162","article-title":"Medication treatment for opioid use disorders in substance use treatment facilities","volume":"38","author":"Mojtabai","year":"2019","journal-title":"Health Affairs (Millwood)"},{"issue":"7","key":"10.1016\/j.josat.2024.209568_bb0150","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1176\/appi.ps.201900025","article-title":"The Affordable Care Act and opioid agonist therapy for opioid use disorder","volume":"70","author":"Mojtabai","year":"2019","journal-title":"Psychiatric Services"},{"key":"10.1016\/j.josat.2024.209568_bb0160","article-title":"May 1","author":"National Academy for State Health Policy","year":"2018","journal-title":"Medicaid expansion in Maine moves from the legislature to the courts"},{"key":"10.1016\/j.josat.2024.209568_bb0165","article-title":"State unintentional drug overdose reporting system (SUDORS)","author":"National Center for Health Statistics","year":"2022","journal-title":"Centers for Disease Control and Prevention"},{"key":"10.1016\/j.josat.2024.209568_bb0170","article-title":"Drug overdose surveillance and epidemiology","author":"National Center for Health Statistics","year":"2023","journal-title":"Centers for Disease Control and Prevention"},{"issue":"3","key":"10.1016\/j.josat.2024.209568_bb0175","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/j.sapharm.2023.12.001","article-title":"Is there a disparity in medications for opioid use disorder based on race\/ethnicity and gender? A systematic review and meta-analysis","volume":"20","author":"Nedjat","year":"2024","journal-title":"Research in Social and Administrative Pharmacy"},{"key":"10.1016\/j.josat.2024.209568_bb0180","article-title":"Telehealth initiation of buprenorphine for opioid use disorder: Patient characteristics and outcomes","author":"Nguyen","year":"2023","journal-title":"Journal of General Internal Medicine."},{"key":"10.1016\/j.josat.2024.209568_bb0185","article-title":"Healthcare coverage and service access for low-income adults with substance use disorders","volume":"137","author":"Olfson","year":"2022","journal-title":"Journal of Substance Use & Addiction Treatment"},{"issue":"6","key":"10.1016\/j.josat.2024.209568_bb0190","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2020.8279","article-title":"Combined pharmacotherapy and cognitive behavioral therapy for adults with alcohol or substance use disorders: A systematic review and meta-analysis","volume":"3","author":"Ray","year":"2020","journal-title":"JAMA Network Open"},{"issue":"4","key":"10.1016\/j.josat.2024.209568_bb0195","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1080\/08897077.2016.1189477","article-title":"Medication-assisted treatment for substance use disorders within a national community health center research network","volume":"37","author":"Rieckmann","year":"2016","journal-title":"Substance Abuse"},{"issue":"2","key":"10.1016\/j.josat.2024.209568_bb2195","doi-asserted-by":"crossref","first-page":"2218","DOI":"10.1016\/j.jeconom.2023.03.008","article-title":"What\u2019s trending in difference-in-differences? A synthesis of the recent econometrics literature","volume":"235","author":"Roth","year":"2023","journal-title":"Journal of Econometrics"},{"issue":"6","key":"10.1016\/j.josat.2024.209568_bb0200","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1016\/j.amepre.2017.06.009","article-title":"Geographic variation in opioid and heroin involved drug poisoning mortality rates","volume":"53","author":"Ruhm","year":"2017","journal-title":"American Journal of Preventive Medicine"},{"issue":"4","key":"10.1016\/j.josat.2024.209568_bb0205","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2018.1588","article-title":"Changes in buprenorphine-naloxone and opioid pain reliever prescriptions after the affordable care act Medicaid expansion","volume":"1","author":"Saloner","year":"2018","journal-title":"JAMA Network Open"},{"issue":"3","key":"10.1016\/j.josat.2024.209568_bb0210","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1377\/hlthaff.2019.01428","article-title":"Specialty substance use disorder treatment admissions steadily increased in the four years after Medicaid expansion","volume":"39","author":"Saloner","year":"2020","journal-title":"Health Affairs (Millwood)"},{"issue":"5","key":"10.1016\/j.josat.2024.209568_bb0215","doi-asserted-by":"crossref","first-page":"917","DOI":"10.2105\/AJPH.2012.301049","article-title":"Opioid agonist treatments and heroin overdose deaths in Baltimore, Maryland, 1995-2009","volume":"103","author":"Schwartz","year":"2013","journal-title":"American Journal of Public Health"},{"key":"10.1016\/j.josat.2024.209568_bb0220","unstructured":"Searing, A. (2018, may 30). Why Virginia expanded Medicaid: Five key reasons. Center for Children & Families (CFF) of the Georgetown University McCourt School of Public Policy. https:\/\/ccf.georgetown.edu\/2018\/05\/30\/why-virginia-expanded-medicaid-five-key-reasons\/."},{"issue":"5","key":"10.1016\/j.josat.2024.209568_bb0225","doi-asserted-by":"crossref","first-page":"642","DOI":"10.2105\/AJPH.2018.304338","article-title":"Impact of Medicaid expansion on access to opioid analgesic medications and medication-assisted treatment","volume":"108","author":"Sharp","year":"2018","journal-title":"American Journal of Public Health"},{"issue":"3","key":"10.1016\/j.josat.2024.209568_bb0230","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1080\/10550490600625624","article-title":"Characterizing the emerging population of prescription opioid abusers","volume":"15","author":"Sigmon","year":"2006","journal-title":"American Journal of Addictions"},{"key":"10.1016\/j.josat.2024.209568_bb0235","article-title":"Association between availability of medications for opioid use disorder in specialty treatment and use of medications among patients: A state-level trends analysis","volume":"132","author":"Solomon","year":"2022","journal-title":"Journal of Substance Use & Addiction Treatment"},{"issue":"2","key":"10.1016\/j.josat.2024.209568_bb0240","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/S0193-953X(05)70081-2","article-title":"Medical consequences of substance abuse","volume":"22","author":"Stein","year":"1999","journal-title":"Psychiatric Clinics of North America"},{"key":"10.1016\/j.josat.2024.209568_bb0245","unstructured":"Substance Abuse and Mental Health Services Administration (SAMHSA). (2023a). Key substance use and mental health indicators in the United States: Results from the 2021 National Survey on drug use and health. (HHS Publication No. PEP22\u201307\u201301-005, NSDUH Series H-57). Rockville, MD Retrieved from https:\/\/www.samhsa.gov\/data\/report\/2021-nsduh-annual-national-report."},{"key":"10.1016\/j.josat.2024.209568_bb0250","unstructured":"Substance Abuse and Mental Health Services Administration (SAMHSA). (2023b). Waiver elimination (MAT Act). Retrieved August 23, 2023 from https:\/\/www.samhsa.gov\/medications-substance-use-disorders\/waiver-elimination-mat-act."},{"key":"10.1016\/j.josat.2024.209568_bb0255","article-title":"Treatment episode data set (TEDS) admissions, 2020","author":"Substance Abuse and Mental Health Services Administration (SAMHSA), & Center for Behavioral Health Statistics and Quality","year":"2022","journal-title":"Substance Abuse and Mental Health Services Administration (SAMHSA)"},{"issue":"2","key":"10.1016\/j.josat.2024.209568_bb2255","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.jeconom.2020.09.006","article-title":"Estimating dynamic treatment effects in event studies with heterogeneous treatment effects","volume":"225","author":"Sun","year":"2021","journal-title":"Journal of Econometrics"},{"key":"10.1016\/j.josat.2024.209568_bb0265","doi-asserted-by":"crossref","DOI":"10.1016\/j.josat.2023.209059","article-title":"Impact of Medicaid expansion on inclusion of medications for opioid use disorder in homeless adults' treatment plans","volume":"152","author":"Swartz","year":"2023","journal-title":"Journal of Substance Use & Addiction Treatment"},{"issue":"12","key":"10.1016\/j.josat.2024.209568_bb0270","doi-asserted-by":"crossref","first-page":"1974","DOI":"10.1001\/jamainternmed.2014.5416","article-title":"Association of opioid agonist therapy with lower incidence of hepatitis C virus infection in young adult injection drug users","volume":"174","author":"Tsui","year":"2014","journal-title":"JAMA Internal Medicine"},{"key":"10.1016\/j.josat.2024.209568_bb0275","doi-asserted-by":"crossref","unstructured":"Volkow, N. D., Frieden, T. R., Hyde, P. S., & Cha, S. S. (2014). Medication-assisted therapies--tackling the opioid-overdose epidemic. New England Journal of Medicine, 370(22), 2063\u20132066. doi:https:\/\/doi.org\/10.1056\/NEJMp1402780.","DOI":"10.1056\/NEJMp1402780"},{"issue":"2","key":"10.1016\/j.josat.2024.209568_bb0280","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2019.20622","article-title":"Comparative effectiveness of different treatment pathways for opioid use disorder","volume":"3","author":"Wakeman","year":"2020","journal-title":"JAMA Network Open"},{"issue":"4","key":"10.1016\/j.josat.2024.209568_bb0285","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1097\/MLR.0000000000000703","article-title":"Impact of Medicaid expansion on Medicaid-covered utilization of buprenorphine for opioid use disorder treatment","volume":"55","author":"Wen","year":"2017","journal-title":"Medical Care"},{"key":"10.1016\/j.josat.2024.209568_bb0290","article-title":"Full Medicaid expansion beings in Utah. Here\u2019s how to check if you qualify","author":"Wood","year":"2020","journal-title":"The Salt Lake Tribune"}],"container-title":["Journal of Substance Use and Addiction Treatment"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2949875924002807?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2949875924002807?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,12,4]],"date-time":"2024-12-04T06:19:27Z","timestamp":1733293167000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2949875924002807"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":57,"alternative-id":["S2949875924002807"],"URL":"https:\/\/doi.org\/10.1016\/j.josat.2024.209568","relation":{},"ISSN":["2949-8759"],"issn-type":[{"value":"2949-8759","type":"print"}],"subject":[],"published":{"date-parts":[[2025,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Medicaid expansion and medications to treat opioid use disorder in outpatient specialty care from 2010 to 2020","name":"articletitle","label":"Article Title"},{"value":"Journal of Substance Use and Addiction Treatment","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.josat.2024.209568","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"209568"}}